← Back to Clinical Trials
Recruiting NCT06405464
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Trial Parameters
Condition HIV Infections
Sponsor University of Zurich
Study Type OBSERVATIONAL
Phase N/A
Enrollment 600
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-03-01
Completion 2025-12-31
Interventions
VOCABRIA 30Mg TabletEDURANT 25Mg TabletCabotegravir Injectable Suspension
Brief Summary
This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.
Eligibility Criteria
Inclusion Criteria: * Participant in the SHCS * All SHCS participants initiating the CAB+RPV LA regimen * All SHCS participants on SOC oral regimen Exclusion Criteria: * Not participating in the SHCS
Related Trials
NCT06405464
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and
View Trial →
NCT06005298
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT I
View Trial →
NCT07428330
Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With
View Trial →